Aileron Therapeutics, Inc. Profile Avatar - Palmy Investing

Aileron Therapeutics, Inc.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell…

Biotechnology
US, Boston [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Aileron Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Aileron Therapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Aileron Therapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of ALRN's Analysis
CIK: 1420565 CUSIP: 00887A105 ISIN: US00887A2042 LEI: - UEI: -
Secondary Listings
ALRN has no secondary listings inside our databases.